Zoetis (NYSE:ZTS) Given New $210.00 Price Target at Stifel Nicolaus

Zoetis (NYSE:ZTS) had its price target upped by Stifel Nicolaus from $200.00 to $210.00 in a report released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

ZTS has been the subject of a number of other reports. Argus upgraded Zoetis to a strong-buy rating in a research report on Friday, August 9th. Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an overweight rating in a research report on Wednesday, August 14th. Finally, BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a buy rating in a research note on Monday, August 12th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of Buy and a consensus price target of $218.22.

Zoetis Stock Up 0.4 %

ZTS stock opened at $196.48 on Wednesday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a market capitalization of $89.65 billion, a P/E ratio of 37.86, a P/E/G ratio of 2.98 and a beta of 0.88. Zoetis has a 52-week low of $144.80 and a 52-week high of $201.92. The company’s 50 day simple moving average is $184.11 and its 200-day simple moving average is $174.31.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.41 EPS. As a group, equities research analysts anticipate that Zoetis will post 5.84 EPS for the current year.

Hedge Funds Weigh In On Zoetis

Several hedge funds have recently bought and sold shares of ZTS. Webster Bank N. A. boosted its stake in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares in the last quarter. Quarry LP boosted its position in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. Neo Ivy Capital Management bought a new stake in Zoetis during the fourth quarter worth approximately $40,000. LRI Investments LLC acquired a new position in Zoetis during the first quarter valued at approximately $43,000. Finally, Hazlett Burt & Watson Inc. raised its position in shares of Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after purchasing an additional 102 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.